GlobeNewswire

Nexstim NBT® System with SmartFocus® TMS sold to Neurological Institute of Los Angeles

Share

Press release, Helsinki, 27 August 2020 at 14.30 (EEST)

Nexstim NBT® System with SmartFocus® TMS sold to Neurological Institute of Los Angeles

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that Neurological Institute of Los Angeles has purchased a Nexstim NBT® System with SmartFocus® TMS.

The Neurological Institute of Los Angeles (NILA) is a comprehensive, private neurological center that is focused on providing personalized patient care and on advancing neuroscience through novel research and clinical trials. They use Nexstim SmartFocus® TMS technology for depression therapy and research.

This is the fifth Nexstim NBT® system installed for depression treatment in California.

Mikko Karvinen, CEO of Nexstim, said: “We are happy to announce that The Neurological Institute of Los Angeles has decided to purchase the NBT® system after an evaluation period. SmartFocus® TMS continues to be subject of intensive research also outside its clinically validated indications which highlights its possible potential to treat a host of currently intractable brain diseases and disorders.”

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com

About Nexstim Plc

Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information please visit www.nexstim.com

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

SEK TENDER OPERATION ANNOUNCEMENT FOR ONWARD LENDING30.9.2020 16:20:00 CESTPress release

SEK TENDER OPERATION ANNOUNCEMENT FOR ONWARD LENDING 2020-10-02 Transaction type:SEK CreditTender date:2020-10-02Time for submission of bids:10.30-11.00 (CEST)Payment date:2020-10-06Final repayment date2024-10-07Offered volume:50 billion SEKMinimum bid amount:10 million SEKMaximum bid amount:12.5 billion SEKMaximum number of bids from each participant: 1Interest rate:0.00 %Additional interest rate:0.10 per cent ALL APPROVED COUNTERPARTIES ARE INVITED TO SUBMIT VOLUME BIDS TO THE RIKSBANK (46-8-6966970) BY 11.00 ON OCTOBER 2 2020, AT THE LATEST. CONFIRMATION ON E-MAIL: eol@riksbank.se Result of the auction will be published at 11.30 (CEST) on Tender date. Complete terms and conditions can be retrieved at http://www.riksbank.se

Change in numbers of shares and votes in Saniona AB (publ)30.9.2020 16:00:00 CESTPress release

PRESS RELEASE September 30, 2020 During September, the registered number of shares and votes in Saniona AB (publ) (“Saniona”) has increased due to the exercising of warrants of series TO 2. As of September 30, 2020, the registered number of shares and votes in Saniona amounts to 62,372,831. For more information, please contact Trista Morrison, Chief Communications Officer. Mobile + 1 (858) 229 1738. Email: trista.morrison@saniona.com This information is such information as Saniona AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 4 p.m. CET on September 30, 2020. About Saniona Saniona is a rare disease biopharmaceutical company focused on research, development and commercialization of treatments for the central nervous system. The company has four programs in clinical development. Saniona intends to develop and commercialize treatments f

Ändring av antalet aktier och röster i Saniona AB (publ)30.9.2020 16:00:00 CESTPressemelding

PRESSMEDDELANDE 30 september 2020 Under september månad har det registrerade antalet aktier och röster i Saniona AB (publ) (”Saniona”) ökat till följd av utnyttjandet av teckningsoptioner av serie TO 2. Per den 30 september 2020 uppgår antalet registrerade aktier och röster i Saniona till 62 372 831. För mer information, vänligen kontakta Trista Morrison, Chief Communications Officer. Telefon + 1 (858) 229 1738. Epost: trista.morrison@saniona.com Denna information är sådan information som Saniona AB (publ) är skyldig att offentliggöra enligt lagen om handel med finansiella instrument. Informationen lämnades för offentliggörande via kontaktpersonen som anges ovan, klockan 16:00 CET den 30 september 2020. Om Saniona Saniona är ett biofarmaceutiskt företag som fokuserar på forskning, utveckling och kommersialisering av behandlingar mot sällsynta sjukdomar i centrala nervsystemet. Bolaget har fyra program i klinisk utveckling. Saniona har för avsikt att utveckla och kommersialisera behandl

Auriant Mining AB (publ.) announces changes in its geological team30.9.2020 14:10:09 CESTPress release

The Board of Directors of Auriant Mining AB (publ.) (the “Company”) announces the departure of Chief Geologist Vladimir Churin, who leaves the Company to pursue other opportunities, and consequent changes in its geological team. The Board is reviewing its future requirements in this team, which in the meantime will continue under the leadership of Senior Geologist, Artem Manshin who has been with the Company for 7 years. Danilo Lange, CEO of Auriant Mining said: “On behalf of Auriant, I would like to thank Vladimir for his service to the Company and the role he has played in developing our asset portfolio, and in particular the successful exploration of the Barsuchiy and Pravoberezhny deposits. We wish him well in his future career. Our review is being carried out as the Board works to ensure we achieve the right balance of skills across all our core disciplines, as the Company prepares for the next stage of its development and in particular unlocking further value in its Tardan and Ka

Auriant Mining AB (publ.) tillkännager förändringar i geologigruppen30.9.2020 14:10:09 CESTPressemelding

Styrelsen för Auriant Mining AB (publ.) (”Bolaget”) meddelar avgång av chefsgeolog, Vladimir Churin, som lämnar Bolaget för att utöva andra möjligheter och till följd av förändringar i geologigruppen. Styrelsen arbetar med en översyn av sina framtida krav i detta team, som under den tiden kommer att fortsätta under ledning av seniorgeolog, Artem Manshin, som har varit anställd i Bolaget i 7 år. Danilo Lange, VD för Auriant Mining, kommenterade: ”På uppdrag av Auriant, vill jag tacka Vladimir för hans tjänst till Bolaget och den roll han har spelat för att utveckla vår tillgångsportfölj och i synnerhet den framgångsrika prospekteringen av fyndigheterna Barsuchiy och Pravoberezhny. Vi önskar honom lycka till i sin framtida karriär. Vår granskning genomförs när styrelsen arbetar för att säkerställa att vi uppnår rätt kompetensbalans inom alla våra kärnområden, eftersom Bolaget förbereder sig för nästa steg i sin utveckling och särskilt upplåsning av ytterligare värde av sina tillgångar i